Clostridioides difficile infections (CDIs), and particularly recurrent infections, cause a
significant burden on the health-care system. Bezlotoxumab is a new agent for the …

Clostridium difficile infection (CDI) continues to possess a significant disease burden in the
United States (US) as well as all over the world. Given the increase in severity and …

Toxigenic culture and cytotoxicity assays are standard tests for detecting C. difficile infection
(CDI). Others include immunochromatographic strips, a rapid diagnostic test that detects …

Objective: Clostridioides difficile infection and recurrent C. difficile infection result in
substantial economic burden and healthcare resource use. Sepsis and bowel surgery are …

The commercial macrolide antibiotic fidaxomicin was synthesized in a highly convergent
manner. Salient features of this synthesis include a β-selective noviosylation, a β-selective …

Clostridioides difficile infection (CDI) is a common infectious disease that is mainly caused
by antibiotics. Antibiotic therapy is still the dominant treatment for CDI, although it is …

Background Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic
against Clostridioides difficile) achieve reductions in recurrence rates of C. difficile infection …

Objective: To describe mortality, healthcare resource utilization (HRU), and costs among
Medicare beneficiaries with primary Clostridioides difficile infection (pCDI) or recurrent CDI …

Summary Background Novel drugs for Clostridium difficile (C. difficile) infections have been
proven to reduce recurrent infections. Because of their high financial costs, identification of …

Hospital readmission with Clostridium difficile infection as... : Medicine Hospital readmission
with Clostridium difficile infection as a secondary diagnosis is associated with worsened …